Kyushu University Academic Staff Educational and Research Activities Database
List of Reports
Isamu Okamoto Last modified date:2019.06.25

Lecturer / Research Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyushu University / Respiratory Medicine / Kyushu University Hospital


Reports
1. Keunchil Park. Darren Wan-Teck Lim, Okamoto I. & James Chih-Hsin Yang , First-line afatinib for the treatment of EGFR mutationpositive non-small cell lung cancer in the ‘real-world’ clinical setting, Therapeutic Advances in Medical Oncology 11, 1-17, 2019.01.
2. Otsubo K., Okamoto I , Hamada N.& Nakanishi Y., Anticancer drug treatment for advanced lung cancer with interstitial lung disease., Respiratory Investigation. 56(4), 307-311, 2018.07.
3. Iwama E., Nakanishi Y. & Okamoto I., Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer., Expert Review of Anticancer Therapy 18(3), 267-276, 2018.04.
4. Ogata H., Okamoto I.,* Yoshimoto G., Obara T., Ijichi K., Iwama E., Harada T., Akashi K. & Nakanishi Y. , Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

, Respiratory Investigation 55(2),, 2017.03.
5. Ogata H., Iwama E., Yamamoto Y., Kato K., Harada T., Oda Y, Nakanishi Y. & Okamoto I.* , Severe aplastic anemia during osimertinib therapy in a patient with EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer
, Journal of Thoracic Oncology 12(5), 2017.05.
6. Yanagihara T., Tanaka K., Ota K., Kashiwagi E., Takeuchi A., Tatsugami K, Eto M, Nakanishi Y. & Okamoto I.* , Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment
, Annals of Oncology 28(8), 2017.08.
7. Ikematsu Y., Yoneshima Y., Ijichi K., Tanaka K., Harada T., Oda Y, Nakanishi Y. & Okamoto I.*, Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1, Lung Cancer, 2017.07.
8. Otsubo K., Nakatomi K., Furukawa R., Ashida K., Yoneshima Y., Nakanishi Y. & Okamoto I.* , Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab, Annals of Oncology , 2017.08.
9. Otsubo K., Seki N., Nakanishi Y. & Okamoto I.* , Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non–small cell lung cancer., Annals of Oncology , 2017.10.
10. Kojima K., Okamoto I., Ushijima S., Yoshinaga T., Kitaoka M., Suga M., Sasaki Y., Successful treatment of primary pulmonary angiosarcoma.
, Chest, 2003.12.
11. Okamoto I., Fujii K., Matsumoto M., Terasaki Y., Kihara N., Kohrogi H., Suga M., Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.
, Lung Cancer, 2003.06.
12. Okamoto I., Iyonaga K., Fujii K., Mori T., Yoshioka M., Kohrogi H., Matsumoto M., Suga M., Absence of gallium uptake in unicentric and multicentric Castleman's disease
, Internal Medicine, 2003.08.
13. Araki J., Okamoto I., Suto R., Ichikawa Y., Sasaki J., Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
, Lung Cancer, 2005.04.
14. Kurata T., Tamura K., Okamoto I., Satoh T., Nakagawa K., Fukuoka M., Pemetrexed-induced edema of the eyelid.
, Lung Cancer, 2006.11.
15. Okamoto I., Araki J., Suto R., Shimada M., Nakagawa K., Fukuoka M., EGFR mutation in gefitinib-responsive small-cell lung cancer.
, Annals of Oncology, 2006.06.
16. Morinaga R., Okamoto I., Furuta K., Kawano Y., Sekijima M., Dote K., Satou T., Nishio K., Fukuoka M., Nakagawa K., Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.

, Lung Cancer , 2007.12.
17. Takezawa K., Okamoto I., Fukuoka J., Tanaka K., Kaneda H., Uejima H., Yoon H., Imakita M., Fukuoka M., Nakagawa K., Large cell neuroendocrine carcinoma of the mediastinum with α-fetoprotein production.

, Journal of Thoracic Oncology, 2008.02.
18. Takezawa K., Okamoto I., Fukuoka M., Nakagawa K., Pharmacokinetic analysis of carboplatin and etoposide in a small cell lung cancer patient undergoing hemodialysis.

, Journal of Thoracic Oncology , 2008.09.
19. Okamoto K., Tsurutani J., Terashima M., Okamoto I., Nakagawa K., Zoledronic acid-induced regression of multiple metastases at nonskeletal sites.

, Annals of Oncology, 2009.04.
20. Takeda M., Okamoto I., Makimura C., Fukuoka M., Nakagawa K., Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.

, Journal of Thoracic Oncology, 2010.07.
21. Takeda M., Okamoto I., Fukuoka M., Nakagawa K., Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity
, Journal of Clinical Oncology , 2010.06.
22. Takeda M., Okamoto I., Sakai K., Tanaka K., Terashima M., Nishio K., Nakagawa K., Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.
, Clinical Lung Cancer, 2012.03.
23. Kaneda H., Okamoto I., Nakagawa K., Pharmacokinetics of docetaxel in a patient with non–small cell lung cancer undergoing continuous ambulatory peritoneal dialysis

, Journal of Thoracic Oncology, 2012.03.
24. Hayashi H., Okamoto I., Nakagawa K., Perirenal hematoma associated with Bevacizumab
, Investigational New Drugs, 2012.04.
25. Kaneda H., Okamoto I., Satoh T., Nakagawa K., Reversible posterior leukoencephalopathy syndrome and trastuzumab.

, Investigational New Drugs , 2012.08.
26. Kaneda H., Okamoto I., Sakai K., Tanizaki J., Takeda M., Nishio K., Nakagawa K., Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma

, Acta Oncologica, 2012.09.
27. Kawakami H., Nishina S., Ueda S., Kudo T., Okamoto W., Kurata T., Okamoto I., Nakagawa K., Capecitabine Plus Cisplatin Treatment for Advanced Gastric Cancer in a Patient with Hepatic Impairment Secondary to Metastases

, Gastrointestinal Cancer Research, 2012.05.
28. Tamiya A., Okamoto I., Miyazaki M., Shimizu S., Kitaichi M., Nakagawa K., Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK–positive non–small cell lung cancer.

, Journal of Clinical Oncology, 2013.01.
29. Matsuoka H., Kurata T., Okamoto I., Kaneda H., Tanaka K., Nakagawa K., Clinical response to crizotinib retreatment after acquisition of drug resistance.

, Journal of Clinical Oncology, 2013.07.
30. Kaneda H., Okamoto I., Nakagawa K., Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small cell lung cancer.

, Journal of Thoracic Oncology , 2013.04.
31. Okamoto K., Okamoto I., Miyazaki M., Tanaka K., Kaneda H., Nakagawa K, Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer.

, Investigational New Drugs, 2013.10.
32. Fujiwara A., MD., Kanou T., Tokunaga T., Oami J., Kodama K., Nishino K., Tomita Y., Okamoto I., Bilateral ovarian metastasis of non-small cell lung cancer with ALK rearrangement

, Lung Cancer, 2014.02.
33. Hayashi H., Okamoto I., Tanizaki J., Tanaka K., Okuda T., Kato A., Nishimura Y., Nakagawa K., Cystic brain metastasis in non–small cell lung cancer with ALK rearrangement.
, Journal of Clinical Oncology, 2014.12.
34. Yoneshima Y., Okamoto I., Arima-Omori M., Kimura S., Hidaka-Fujimoto N., Iwama E., Harada T., Takayama K., Nakanishi Y., Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement

, Investigational New Drugs, 2015.04.
35. Yoneshima Y., Okamoto I., Enokizu A., Iwama E., Harada T., Takayama K., Nakanishi Y., Successful Treatment with Alectinib after Crizotinib-Induced Esophageal Ulceration
, Lung Cancer, 2015.06.
36. Okamoto I., Suga M., Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?
, Internal Medicine, 2003.10.
37. Kurata T., Okamoto I., Tamura K., Fukuoka M., Amrubicin for non-small-cell lung cancer and small-cell lung cancer.

, Investigational New Drugs , 2007.10.
38. Okamoto I., Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan.

, International Journal of Clinical Oncology, 2008.04.
39. Okamoto I., Fukuoka M., S-1: a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer.
Clinical Lung Cancer
, 2009.07.
40. Okamoto I., Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.

, FEBS Journal, 2010.01.
41. Okamoto I., Mitsudomi T., Nakagawa K., Fukuoka M., The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations

, Therapeutic Advences in Medical Oncology. , 2010.09.
42. Takeda M., Okamoto I., Nishimura Y., Nakagawa K., Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non–small cell lung cancer.
, Lung Cancer: Targets and Therapy, 2011.10.
43. Okamoto I., Nakagawa K., EML4-ALK-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects

, Cancer Science , 2012.08.
44. Kaneda H., Yoshida T., Okamoto I., Molecularly targeted approaches herald a new era of non–small cell lung cancer treatment.
, Cancer Management and Research , 2013.06.
45. Iwama E., Okamoto I., Harada T., Takayama K., Nakanishi Y., Development of ALK inhibitors and molecular diagnosis in ALK rearrangement–positive lung cancer.
, OncoTargets and Therapy, 2014.03.
46. Kawakami H., Okamoto I., Okamoto W., Tanizaki J., Nakagawa K., Nishio K., Targeting MET amplification as a new oncogenic driver
, Cancers, 2014.07.
47. Kawano Y., Okamoto I., Fukuda H., Ohe Y., Nakamura S., Nakagawa K., Hotta K., Kiura K., Takiguchi Y., Saka H., Okamoto H., Takayama K., Semba H., Kobayashi K., Kenmotsu H., Tsuboi M., Yamamoto N., Nukiwa T., Nakanishi Y., Current status and future perspectives of cooperative study groups for lung cancer in Japan.
, Respiratory Investigation, 2014.11.